(Q35561947)

8 August 2017

1 reference

title

Switching between beta blockers in heart failure patients: rationale and practical considerations (English)

1 reference

8 August 2017

Switching Between Beta Blockers in Heart Failure Patients: Rationale and Practical Considerations (English)

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

22 March 2024

1 reference

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

22 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

22 March 2024

author name string

William T. Abraham

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564146

22 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14564146

22 March 2024

publication date

1 September 2003

1 reference

full work available at URL

8 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1527-5299.2003.02001.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14564146

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1527-5299.2003.02001.x

22 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1527-5299.2003.02001.x

22 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

22 March 2024

published in

Congestive Heart Failure

1 reference

8 August 2017

volume

9

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

271-278

1 reference

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2003.02001.X

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

22 March 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

22 March 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials

22 March 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

The evidence for beta blockers in heart failure

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Consensus recommendations for the management of chronic heart failure

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effect of carvedilol on survival in severe chronic heart failure

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

22 March 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Mechanism of action of beta-blocking agents in heart failure

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

beta-adrenergic receptor blockade in chronic heart failure

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Ischemic and nonischemic heart failure do not require different treatment strategies

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure

22 March 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

22 March 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Adverse consequences of high sympathetic nervous activity in the failing human heart

22 March 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage

22 March 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Ventricular remodeling and its prevention in the treatment of heart failure

22 March 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

22 March 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Adrenergic effects on the biology of the adult mammalian cardiocyte

22 March 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

22 March 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Molecular and cellular mechanisms of myocardial failure

22 March 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

22 March 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes

22 March 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy.

22 March 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Coronary vasoconstriction and catecholamine cardiomyopathy.

22 March 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers

22 March 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

22 March 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

22 March 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy

22 March 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade

22 March 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure

22 March 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

22 March 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy

22 March 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Selective beta 1-adrenoceptor blockade enhances positive inotropic responses to endogenous catecholamines mediated through beta 2-adrenoceptors in human atrial myocardium

22 March 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death

22 March 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

The role of third-generation beta-blocking agents in chronic heart failure

22 March 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

The pharmacology of carvedilol

22 March 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

22 March 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

22 March 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

22 March 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.

22 March 2024

53

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis

22 March 2024

54

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger

22 March 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids

22 March 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction

22 March 2024

57

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury

22 March 2024

58

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol inhibits vascular smooth muscle cell proliferation.

22 March 2024

59

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol

22 March 2024

60

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol

22 March 2024

61

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture

22 March 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

22 March 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents?

22 March 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension

22 March 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure

22 March 2024

70

1 reference

https://api.crossref.org/works/10.1111/J.1527-5299.2003.02001.X

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference